Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients

Arthritis Rheum. 1988 Mar;31(3):378-85. doi: 10.1002/art.1780310309.


Anticentromere antibodies (ACA) and anti-topoisomerase I (anti-topo I) were assayed in serum samples from 355 patients: 89 with proximal scleroderma; 54 with CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias), without proximal scleroderma; 154 with primary and secondary Raynaud's disease; and 58 with other rheumatic diseases, without Raynaud's disease. Sera from healthy control subjects were also assayed. Using immunoblotting techniques, anti-topo I was detected in 28% of the patients with proximal scleroderma; using immunodiffusion techniques, this antibody was found in only 20% of the same group of patients. Anti-topo I and ACA were found primarily in patients with scleroderma, CREST syndrome, and Raynaud's phenomenon. ACA identified patients with less severe disease, whereas anti-topo I identified patients with skin and cardiac involvement and patients with malignancies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Antibodies / analysis*
  • Centromere / immunology*
  • Chromosomes / immunology*
  • DNA Topoisomerases, Type I / immunology*
  • Demography
  • Humans
  • Middle Aged
  • Neoplasms / complications
  • Neoplasms / immunology
  • Rheumatic Diseases / immunology*
  • Rheumatic Diseases / mortality
  • Rheumatic Diseases / pathology
  • Scleroderma, Systemic / immunology*
  • Severity of Illness Index
  • Skin / pathology
  • Syndrome


  • Antibodies
  • DNA Topoisomerases, Type I